IXICO plc - IXICO to Present at HD and Ataxia Conferences
("IXICO" or the "Company")
IXICO to Present Abstracts at Upcoming Huntington's Disease and Ataxia Conferences
IXICO will present a poster entitled "A Fully Automatic Pipeline for Estimation of Putamen and Caudate Volume" on 7 November at
The abstract outlines a method for fully automated segmentation of the caudate and putamen brain structures using IXICO's proprietary LEAP™ algorithm technology as applied to a Huntington disease cohort.
In addition, IXICO is supporting the event as 'Friends of HSG' and the company's biomarker scientist, Dr Kirsi Kinnunen, will be participating in the 'Ask the Expert' panel for the HSG Family Day on Saturday 9th November.
IXICO will present an abstract entitled "Fully automated measurement of brainstem and cerebellar volume: imaging endpoint for Ataxia, PSP and FA in multicenterclinical trial studies" on 14 November at
The abstract describes the scientific validation of a fully-automated volumetric assessment of cerebellar and brainstem regions as well as operational considerations for successful deployment in clinical trials.
Giulio Cerroni, Chief Executive Officer of IXICO commented: "We are delighted to be presenting abstracts on some of our pioneering data analytics at these upcoming conferences. As new therapies for neurodegenerative diseases enter clinical development, the improvement and validation of image analysis pipelines using AI technologies, such as LEAP™, can critically support trial design and clinical investigation."
HSG: Richard Joules1, Helen Crawford1, Robin Wolz1, 2 1)
IARC: Abaei M1*, Joules R1, Palombit A1, Faber J2, 3, Klockgether T2, 3, Wolz R1, 4
For further information please contact:
| || |
+44 (0) 20 3763 7498
Giulio Cerroni, Chief Executive Officer
| || |
+44 (0) 203 950 9144
Mary Clark / Supriya Mathur / Charlotte Hepburne-Scott
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
More information is available on www.IXICO.com
About HSG Annual Meeting 2019
Since 1993, the
About IARC 2019
This information is provided by RNS, the news service of the
Quick facts: IXICO PLC
Market Cap: £39.09 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE